Table 3 Clinical features, laboratory characteristics, and outcome in relation to TCRA/D translocation and TCRA/D amplification
Parameters | TCRA/D translocation | p-value | TCRA/D amplification | p-value | |||
|---|---|---|---|---|---|---|---|
Negative | Positive | Negative | Positive | ||||
Age | Median (range) | 7 (2–18) | 6 (1–18) | 0.841 | 6.5 (1–18) | 5 (3–17) | 0.669 |
Hemoglobin (g/dl) | Median (range) | 7.4 (4–15) | 8.4 (5–14) | 0.460 | 7.8 (4–14) | 7.4 (6–15) | 0.625 |
Platelets’ count (× 109/L) | Median (range) | 55 (8–693) | 43 (17–223) | 0.194 | 49 (9–693) | 44 (8–224) | 0.779 |
WBC (× 109/L) | Median (range) | 160 (2–967) | 223 (4–746) | 0.988 | 240 (2–967) | 52 (3–546) | 0.020 |
PB blast% | Median (range) | 80 (0–99) | 85 (0–97) | 0.529 | 85 (0–99) | 50 (0–95) | 0.154 |
BM blast% | Median (range) | 89 (0–99) | 90 (28–98) | 0.784 | 90 (0–99) | 80 (38–92) | 0.050 |
Sex | Male | 29 (67.4%) | 15 (75.0%) | 0.543 | 35 (67.3%) | 9 (81.8%) | 0.341 |
Female | 14 (32.6%) | 5 (25.0%) | 17 (32.7%) | 2 (18.2%) | |||
BM cellularity | Hypercellular | 34 (79.1%) | 17 (85%) | 0.737 | 44 (84.6%) | 7 (63.6%) | 0.197 |
Normocellular | 9 (20.9%) | 3 (15%) | 8 (15.4%) | 4 (36.4%) | |||
CD34 | Negative | 38 (88.4%) | 15 (75%) | 0.266 | 43 (82.7%) | 10 (90.9%) | 0.676 |
Positive | 5 (11.6%) | 5 (25%) | 9 (17.3%) | 1 (9.1%) | |||
ETP | Negative | 38 (88.4%) | 18 (90%) | 0.848 | 49 (94.2%) | 7 (63.6%) | 0.014 |
Positive | 5 (11.6%) | 2 (10%) | 3 (5.8%) | 4 (36.4%) | |||
MCN | Normal | 30 (69.8%) | 16 (80.0%) | 0.629 | 43 (82.7%) | 3 (27.3%) | P < 0.001 |
Hypodiploidy | 5 (11.6%) | 1 (5.0%) | 6 (11.5%) | 0 (0.0%) | |||
Hyperdiploidy | 8 (18.6%) | 3 (15.0%) | 3 (5.8%) | 8 (72.7%) | |||
TCR_B | Negative | 32 (74.4%) | 18 (90.0%) | 0.155 | 44 (84.6%) | 6 (54.5%) | 0.025 |
Positive | 11 (25.6%) | 2 (10.0%) | 8 (15.4%) | 5 (45.5%) | |||
Complex (presence of 3 or more cytogenetics abnormalities) | Negative | 35 (81.4%) | 18 (90.0%) | 0.384 | 47 (90.4%) | 6 (54.5%) | 0.003 |
Positive | 8 (18.6%) | 2 (10.0%) | 5 (9.6%) | 5 (45.5%) | |||
MRD15 | < 0.01 | 6 (19.4%) | 3 (23.1%) | 0.780 | 9 (23.1%) | 0 (0.0%) | 0.566 |
≥ 0.01 | 25 (80.6%) | 10 (76.9%) | 30 (76.9%) | 5 (100%) | |||
MRD42 | < 0.01 | 9 (34.6%) | 6 (37.5%) | 0.850 | 14 (37.8%) | 1 (20.0%) | 0.639 |
≥ 0.01 | 17 (65.4%) | 10 (62.5%) | 23 (62.2%) | 4 (80.0%) | |||
Relapse | Negative | 36 (83.7%) | 19 (95%) | 0.418 | 44 (84.6%) | 11 (100%) | 0.331 |
Positive | 7 (16.3%) | 1 (5%) | 8 (15.4%) | 0 (0.0%) | |||
Early death | Negative | 35 (81.4%) | 17 (85%) | 0.726 | 44 (84.6%) | 8 (72.7%) | 0.389 |
Positive | 8 (18.6%) | 3 (15%) | 8 (15.4%) | 3 (27.3%) | |||
Death | Negative | 21 (48.8%) | 15 (75%) | 0.061 | 31 (59.6%) | 5 (45.5%) | 0.507 |
Positive | 22 (51.2%) | 5 (25%) | 21 (40.4%) | 6 (54.5%) | |||